Source comparison
BPC-157 Dosage Protocol Guide: Dosing Comparison by Research Objective
The table below summarizes dosing ranges cited in published BPC-157 research literature, organized by research objective and administration route. These are not prescriptive recommendations for human use. BPC-157 is not FDA-approved for therapeutic application
This comparison does not assign a generated winner or score.
- The table below summarizes dosing ranges cited in published BPC-157 research literature, organized by research objective and administration route. These are not prescriptive recommendations for human use. BPC-157 is not FDA-approved for therapeutic application. But reflect protocols documented in peer-reviewed animal studies and laboratory investigation reports.
- Acute Gastric Ulcer Repair
- SC or Oral
- 10–20 mcg/kg
- Once daily
- 7–14 days
- Rodent models show mucosal barrier stabilization within 7 days; oral bioavailability lower than SC but gastric-targeted effect observed
- Tendon-to-Bone Healing
- SC or IM (local)
- 10 mcg/kg (~200–350 mcg human equivalent)
- 14–28 days
- IM injection near injury site hypothesized to enhance local VEGF expression; SC systemic dosing shows comparable outcomes
- Muscle Tear Repair
- SC or IM
- 250–500 mcg total daily
- Once or twice daily
- 4–6 weeks
- Split dosing (twice daily) may maintain more consistent plasma levels; aligns with proliferative phase of muscle healing
- Ligament Injury Research
- SC
- 200–400 mcg
- 4–8 weeks
- Longer cycles align with collagen remodeling phase; studies report improved tensile strength at 6–8 weeks vs 4 weeks
- Neuroprotection Models (CNS)
- 10 mcg/kg
- Varies (7–21 days)
- Hypothesized BBB penetration; published models focus on ischemic injury and traumatic brain injury in rodents
- Anti-Inflammatory Research
- 250–350 mcg
- 4 weeks
- TNF-alpha and IL-6 reduction observed in inflammatory bowel disease models; dose-response curve not well-defined
- No single BPC-157 dosage protocol guide serves all research contexts. Dose selection should align with study design, outcome measures, and subject characteristics. The ranges above derive from animal research; human bioequivalent doses calculated using FDA scaling factors (multiply rodent mg/kg dose by 0.16 for human equivalent) produce conservative estimates that many researchers exceed based on anecdotal or observational data not captured in peer-reviewed publications.